Actuate Therapeutics Shows 38% Reduction in Risk of Death in Phase 2 Pancreatic Cancer Trial—Long-Term Survival Data Impresses at ASCO GI 2026

Elraglusib Plus Chemotherapy Significantly Improves Survival Outcomes

Actuate Therapeutics delivered compelling news for the pancreatic cancer community in its latest press release, reporting that patients treated with a combination of elraglusib and standard chemotherapy experienced a 38% lower risk of death compared to those on chemotherapy alone. This finding comes from the company’s robust Phase 2 study (Actuate 1801-Part 3B), which enrolled 286 patients with metastatic pancreatic cancer across multiple international sites and was showcased at the ASCO GI 2026 conference.

Median Overall Survival Extended and Durable Outcomes Observed

The trial’s primary endpoint was median overall survival (OS). The addition of elraglusib lengthened OS to 10.1 months, compared to just 7.2 months for patients receiving chemotherapy (gemcitabine and nab-paclitaxel) alone—a statistically significant difference. More notably, the 12-month survival rate doubled with elraglusib, and the 24-month survival rate rose fivefold, suggesting the possibility of more durable, long-term benefit.

As of November 2025, seventeen patients in the elraglusib arm remained alive, three surpassing 24 months on treatment, compared to none in the chemotherapy-only arm. Given that typical survival for metastatic pancreatic cancer patients is less than 12 months, these results could mark a substantial advance.

Consistent and Manageable Safety Profile Observed

Thankfully, elraglusib did not introduce new safety concerns. Serious treatment-emergent adverse events (TEAEs) were nearly identical between groups—56.1% for elraglusib plus chemotherapy versus 56.4% for chemotherapy alone. Treatment-related deaths and severe adverse events leading to drug stoppage were also similar, suggesting that the extended survival comes without a significant trade-off in tolerability.

Emerging Biomarker Insights Could Guide Future Treatment Strategies

The study didn’t just stop at overall survival. Genomic analysis pointed to potential predictive markers—such as KRAS and ARID1A mutations—that may identify patient subgroups who benefit most from elraglusib. Immunological findings were also promising, with treated patients showing increased levels of CD8+, Granzyme B+, and NK cells in tumors, indicating a more robust anti-tumor immune response. These signals may pave the way for tailored, more effective future regimens as the field moves towards personalization.

Key Takeaways: Is Elraglusib a Step Forward in Pancreatic Cancer Therapy?

For a disease with few meaningful advancements, these results could represent an important step. A 38% reduction in mortality risk and substantial increases in both 12- and 24-month survival stand out in a landscape where most patients do not live a year beyond diagnosis. Safety data gave no reason for pause, and the emerging biomarker insights offer hope for even greater refinement.

However, as Actuate’s management rightly cautioned, these are still interim results. The company will need further studies and may face hurdles such as regulatory review, funding, and real-world testing. For now, though, investors and the oncology community have reason to watch this story closely as it unfolds.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI